a UOC Ematologia , Ospedale dell'Angelo & Ospedale SS. Giovanni e Paolo , Mestre - Venezia , Italy.
b UOC Ematologia , Azienda Ospedaliera Universitaria Integrata, Ospedale Borgo Roma , Verona , Italy.
Expert Rev Hematol. 2016 Jun;9(6):563-77. doi: 10.1586/17474086.2016.1170593. Epub 2016 Apr 8.
Recent developments in immunotherapy are improving treatment results of B-precursor acute lymphoblastic leukemia. This advancement is promoted by new monoclonal antibodies such as inotuzumab ozogamicin, ofatumumab and blinatumomab, by rituximab, and by genetically engineered chimeric antigen receptor-modified T-cells. These treatments, variously targeting CD22, CD20 and CD19 antigens, yield unprecedented high rates of hematologic and molecular remissions even when used in monotherapy and in chemo-resistant or post-transplantation relapsed patients. Beside the encouraging results in relapsed/refractory disease, these agents may open a totally new era in the frontline management of this illness, redefining treatment standards and options for different risk subsets and placing the achievement of a molecular remission at the forefront of treatment objectives. The ever increasing importance of modern immunotherapy in improving treatment design and therapeutic outcome is reviewed.
免疫疗法的最新进展正在改善 B 前体急性淋巴细胞白血病的治疗效果。这一进展得益于新型单克隆抗体，如奥加莫单抗、奥法妥珠单抗和blinatumomab，以及利妥昔单抗和基因工程嵌合抗原受体修饰的 T 细胞。这些治疗方法靶向 CD22、CD20 和 CD19 抗原，即使在单药治疗和化疗耐药或移植后复发的患者中，也能产生前所未有的高血液学和分子缓解率。除了在复发/难治性疾病中取得令人鼓舞的结果外，这些药物还可能在这种疾病的一线治疗中开辟一个全新的时代，重新定义不同风险亚组的治疗标准和选择，并将分子缓解作为治疗目标的重中之重。本文回顾了现代免疫疗法在改善治疗设计和治疗结果方面日益重要的作用。
